Author: NewsEditor

SeaDaddys Nature Center is a tour operator in Crystal River, FL bringing people closer to nature every day for the past 15 years.

Swim with Manatee…

2023 Ventana Research Customer Experience Management Value Index research guide for technology buyers ranked Emplifi in the top 10 vendors based on Emplifi’s usability, manageability, adaptability and validation.

NEW YORK – December 22, 2022 – (Newswire.com)

Emplifi, the leading unified customer experience (CX) platform, today announced that it has been recognized as an Exemplary Vendor in the 2023 Customer Experience Management Value Index report by Ventana Research. Emplifi ranks seventh among 22 vendors, demonstrating critical strengths across a range of product and customer experience capability categories. For a complete copy of the 2023 Ventana Research Customer Experience Management Value Index Report, a research guide used by technology buyers and suppliers, please click here.

“We are thrilled to be recognized by Ventana Research as a leader among 22 notable customer experience management peers,” states Mark Zablan, CEO, Emplifi. “The thorough, independent report showcases Emplifi’s strengths in innovation, usability, manageability, adaptability, and validation – all top criteria for enterprises when selecting a customer engagement platform.” 

As a privately held $1.2 billion valued company, Emplifi is approaching the end of 2022 with strong revenue growth and customer acquisition. Because of its steadfast commitment to continuous innovation, the Emplifi Customer Experience (CX) platform effectively unifies marketing, commerce, and care teams so that brands can effectively support today’s social- and digital-first consumer. Boasting a client list of more than 8,400 global brands  – including all top five retailers, eight of the top 10 automotive companies, and 60% of the Interbrand 100 brands – Emplifi approaches 2023 with impressive momentum and industry recognition with the addition of Ventana Research’s prestigious award.

“Congratulations to Emplifi on its strong showing in Ventana Research’s Customer Experience Management Value Index,” says Keith Dawson, Vice President and Research Director for Customer Experience at Ventana Research. “Emplifi’s efforts to integrate contact center and social media functions into a CXM platform show determination to help organizations make sense of the complex needs of customers.”

Ventana Research’s methodology for The Customer Experience Management Value Index ranks vendors based primarily on their “Product Experience” which accounts for 80% (or four-fifths) of the total evaluation. Other evaluation factors include: Usability (20%), Capability (20%), Reliability (15%), Adaptability (10%), and Manageability (15%). 

Visit our website to learn how Emplifi helps brands bridge the gap between their marketing, commerce, and care capabilities or to receive an in-depth demonstration of Emplifi’s CX platform. 

About Emplifi
Emplifi is the leading unified customer experience (CX) platform that brings marketing, commerce, and care together to help businesses close the customer experience gap. More than 8,400 brands, including Delta Air Lines, Ford Motor Company, and McDonald’s, rely on Emplifi to provide their customers with outstanding experiences at every touchpoint. For more information, visit www.emplifi.io.

Contact Information:

Amlika Lal

International PR Director

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Emplifi Recognized as an Overall Exemplary Vendor by Ventana Research

Know What Exceptional Leaders Know in 2023

What Exceptional Leaders Know Third Edition
TULSA, Okla. – …

NEW YORK – December 22, 2022 – (Newswire.com)

COOLPO today announces the release of its 4K Video Conference Camera with gesture-activated focus, AI-powered auto-framing, 6 microphone array that reduces background noise and targets the speaker plus many more features, which make video calling more interactive and productive. 

In today’s world, remote work is becoming more and more common due to COVID-19, and the reliance on video conferencing continues to grow. So too does the demand for user-friendly conferencing products. Video conferencing participants currently will pay greater attention to the quality of the video conference, and COOLPO sees this opportunity and strives to create smart video conferencing products that better meet today’s needs. 

COOLPO is committed to delivering smart, innovative solutions that exceed the expectations of modern video conferencing users. Therefore, COOLPO newest 4K Webcam was released. With its newest 4K HD conference webcam, COOLPO is changing the way teams collaborate and communicate by harnessing cutting-edge technology to modernize and transform conference room communications. Teams can stay connected and productive, no matter where they are.

With its ultra-high definition lens and advanced audio technology, the COOLPO 4K HD conference camera is the complete solution for remote teams. Some of the key benefits of the COOLPO 4K HD conference camera include:

4K HD Camera: The COOLPO video conference camera captures meetings in stunning 4k resolution and delivers a crisp, clear picture with its ultra-wide 110° field of view. This allows everyone in the meeting to be seen in detail, even if they are sitting on the edges of the frame.
Gesture-Activated Focus: Its advanced AI technology automatically frames attendees, ensuring that the focus stays on whoever is speaking. This means that the camera will zoom in on the person speaking and follow them as they move around the room, ensuring that they are always in focus.
26 Feet Pickup Range: Its 6-microphone array ensures crystal-clear audio with advanced echo cancellation. This means that the microphones will pick up voices from up to 26 feet away, and filter out any background noise, making it easier to hear everyone in the meeting.
Premium Security: Its physical USB connection ensures top-level data security and privacy protection. This means that the camera can’t be hacked or invaded by anyone through wireless connections, ensuring that meetings are secure.
Privacy Protection Cover: The camera also comes with a removable privacy cover, allowing users to easily block the camera when not in use. This ensures that user privacy is protected at all times when they are not using the camera.

In a word, the COOLPO 4K HD conference camera is packed with features that make remote meetings easier and more productive than ever before. It’s available for purchase on Amazon.com and prices start at $499.99. Find out more details on COOLPO 4K Webcam by visiting https://www.amazon.com/dp/B09X5H7T9S.

COOLPO provides numerous other intelligent conference equipment and products as well that can be also found by visiting its Amazon store here: https://www.amazon.com/stores/COOLPOConferenceVideoCamera/page/E52B97D9-42BF-4184-B9F2-EFAF1CC4B42F?ref_=ast_dp_bln_nofrnas_sto&store_ref=bl_ast_dp_nofrnas_sto

Contact Information:

Jerry Lei

Marketing Manager

[email protected]

+86 13824361427

Press Release Service
by
Newswire.com

Original Source:

Revolutionize Remote Meetings With COOLPO’s Newest 4K HD Conference Webcam

NEWARK, Calif. – December 22, 2022 – (Newswire.com)

EyeQue, the leader i…

pixiv will be posting the cumulative total of works posted and the most popular search rankings for 2022.

TOKYO – December 22, 2022 – (Newswire.com)

pixiv, a platform operated by pixiv, Inc. (Headquarters: Shibuya, Tokyo, Representative Director: Shingo Kunieda) is a site where creators can upload illustrations, manga, and novels. pixiv is now launching a time-limited event, “myBESTpixiv2022”, where all users can look back on the past year through their 2022 browsing and posting activities on pixiv.

myBESTpixiv2022 special page: 
https://www.pixiv.net/special/mybestpixiv2022?utm_source=pixiv&utm_medium=content-text&utm_campaign=mybestpixiv&utm_content=press

Users can take a look back on 2022 through their own pixiv user data

“myBESTpixiv2022” is an event whereby users who posted work or browsed work on pixiv in 2022 can look back on their activities throughout the year. A special site is available where users can log in with their pixiv IDs to view their activities history, the work they posted that was most viewed by others, the tags they viewed the most this year, and the work they viewed the most times this year, and generate a card summarizing their activities over the past year.

The cards can be shared on social media or saved as image files. pixiv hopes that all users will have fun looking back on the various ways they enjoyed creative activities on pixiv over the past year.

Event period
Wednesday, Dec. 21, to Saturday, Dec. 31 at 11:59 pm JST

To learn more, please check the special page.
myBESTpixiv2022 special page:
https://www.pixiv.net/special/mybestpixiv2022?utm_source=pixiv&utm_medium=content-text&utm_campaign=mybestpixiv&utm_content=press

*Users who would like to make cards on the special page must log in with their pixiv accounts

Sharing activities on pixiv in the year 2022

pixiv will also announce its overall user status for 2022 on the myBESTpixiv2022 special page. The cumulative total of works posted in 2022 will be announced, as well as the number of creators who posted, the most-searched tags, and other stats.

pixiv extends heartfelt gratitude to the more than 25 million users in Japan and around the world who used the service in 2022.

To achieve its mission of “making creative activities more fun”, pixiv is planning many initiatives to support creators in the coming year, 2023.

■pixiv https://www.pixiv.net/about.php?lang=en
pixiv Inc., provides creator-oriented social networking businesses focused on “communication through artwork”. pixiv launched its service in September 2007, focusing on “making creative activities more fun”, by offering creators a dedicated space to post and share their work (illustrations, manga, and novels). Currently, there are more than 84 million registered users registered on the service.

■pixiv Inc. https://www.pixiv.co.jp
Representative Director: Shingo Kunieda
Established: July 25, 2005
Inquiries: Muramatsu and Takahashi
Email: [email protected]

Contact Information:

Nana Shimazaki

editor, pixivision

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Announcing the launch of pixiv’s time-limited event ‘myBESTpixiv2022’, where users can look back on and share their activities over the past year

Gb Sciences’ innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

LAS VEGAS – December 22, 2022 – (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects related to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses. 

The global anti-inflammatory therapeutics market size was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is expected to hit USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. One key differentiator of Gb Sciences’ CRS therapeutic is the early-intervention and preventative opportunities for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapeutic may also be useful for patients who are experiencing CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T-cells.

“Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of certain viruses. Our cannabis-inspired therapeutics were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself,” said Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures that were designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses, while preserving the immune functions and cytokines necessary to fight viral infections. Gb Sciences recently published a white paper on their novel development program titled “Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics”; download it here. 

A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences’ proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers. Gb Sciences’ MEM, containing either two or three cannabinoids each, reduced the levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the single ingredients tested separately. The ratios of those cannabinoid molecules within the MEM formulations also greatly influenced their anti-inflammatory potential, the study reported. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant-inspired” active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes,” and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Alexis Quintal

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

New Suite of 3GPP Compatible Telecom Software Provides Significant Data Rate & Security

TM Technologies
SAN DIEGO …